Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.

[1]  P. Verde,et al.  The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications’ door , 2020, Oncogene.

[2]  L. Tran,et al.  FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells. , 2020, American journal of translational research.

[3]  S. Bahadur,et al.  Immunotherapy for the Treatment of Breast Cancer: Emerging New Data , 2019, Breast cancer.

[4]  Chunyan Zhao,et al.  Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1 , 2019, Oncogene.

[5]  R. Kuiper,et al.  Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα , 2019, Nature Communications.

[6]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[7]  X. Guan,et al.  Therapeutic landscape in mutational triple negative breast cancer , 2018, Molecular Cancer.

[8]  A. Meindl,et al.  Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history , 2018, BMC Cancer.

[9]  K. Dahlman-Wright,et al.  c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer , 2018, Oncogene.

[10]  Y. Kawaguchi,et al.  A selective inhibition of c-Fos/activator protein-1 as a potential therapeutic target for intervertebral disc degeneration and associated pain , 2017, Scientific Reports.

[11]  D. Berry,et al.  DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial , 2017, npj Breast Cancer.

[12]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[13]  S. Baylin,et al.  Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer. , 2016, Cancer cell.

[14]  Philippe Andrey,et al.  MorphoLibJ: integrated library and plugins for mathematical morphology with ImageJ , 2016, Bioinform..

[15]  Y. Bae,et al.  Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer , 2016, Annals of Surgical Oncology.

[16]  Won-Jun Jang,et al.  Mitochondrial dysfunction induces EMT through the TGF-β/Smad/Snail signaling pathway in Hep3B hepatocellular carcinoma cells. , 2015, International journal of oncology.

[17]  Xiao-guang Chen,et al.  [Design, synthesis and biological evaluation of novel 3-(2-oxo-2-substituted acetamido)benzamides as PARP-1 inhibitors]. , 2015, Yao xue xue bao = Acta pharmaceutica Sinica.

[18]  I. Ellis,et al.  DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers , 2015, Oncotarget.

[19]  Xuesong Yang,et al.  Epithelial‐to‐Mesenchymal Transition Induced by TGF‐β1 Is Mediated by AP1‐Dependent EpCAM Expression in MCF‐7 Cells , 2015, Journal of cellular physiology.

[20]  K. Dahlman-Wright,et al.  AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial–mesenchymal transition in triple-negative breast cancer , 2015, Oncotarget.

[21]  I. Ellis,et al.  Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers? , 2014, Antioxidants & redox signaling.

[22]  E. Wagner,et al.  Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression , 2014, Cell Death and Differentiation.

[23]  T. Lawrence,et al.  Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer , 2014, Clinical Cancer Research.

[24]  L. Newman,et al.  Basal-like and triple-negative breast cancers: searching for positives among many negatives. , 2014, Surgical oncology clinics of North America.

[25]  K. Dahlman-Wright,et al.  Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. , 2014, Cancer research.

[26]  D. Levine,et al.  New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair , 2014, Molecular Cancer Therapeutics.

[27]  Elgene Lim,et al.  Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. , 2013, Cancer cell.

[28]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[29]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[30]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[31]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[32]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[33]  A. Vivacqua,et al.  GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells , 2012, Breast Cancer Research and Treatment.

[34]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[35]  Y. Pommier,et al.  Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. , 2011, Cancer research.

[36]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[37]  J. Lubiński,et al.  PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy , 2011, Breast Cancer Research and Treatment.

[38]  E. Shaulian.  AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise? , 2010, Cellular signalling.

[39]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[40]  J. Russo,et al.  SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis , 2008, Nature.

[41]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[42]  N. Colburn,et al.  Fra-1 a target for cancer prevention or intervention. , 2006, Gene.

[43]  V. Schreiber,et al.  Poly(ADP-ribose): novel functions for an old molecule , 2006, Nature Reviews Molecular Cell Biology.

[44]  Alexander Bürkle,et al.  Poly(ADP‐ribose) , 2005, The FEBS journal.

[45]  Mitsuko Masutani,et al.  A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. , 2003, Nucleic acids research.

[46]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[47]  J. Pietenpol,et al.  Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. , 2002, Toxicology.

[48]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Brigstock,et al.  Connective tissue growth factor: what's in a name? , 2000, Molecular genetics and metabolism.

[50]  G. Poirier,et al.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.

[51]  Kai Huang,et al.  Angiotensin II promotes poly(ADP-ribosyl)ation of c-Jun/c-Fos in cardiac fibroblasts. , 2009, Journal of molecular and cellular cardiology.

[52]  Kai Huang,et al.  PARP-1 suppresses adiponectin expression through poly(ADP-ribosyl)ation of PPAR gamma in cardiac fibroblasts. , 2009, Cardiovascular research.